scholarly journals Prognostic Analysis for Children with Hepatoblastoma with Lung Metastasis: A Single-Center Analysis of 98 Cases

2020 ◽  
Author(s):  
Huimin Hu ◽  
Weiling Zhang ◽  
Yizhuo Wang ◽  
Yi Zhang ◽  
You Yi ◽  
...  
Keyword(s):  
Survival Rate ◽  
Survival Time ◽  
Lung Metastasis ◽  
Standard Treatment ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Factors Affecting ◽  
Prognostic Analysis ◽  
Standardized Treatment ◽  
Lung Metastasectomy

Abstract Background To analyze the factors affecting prognosis of hepatoblastoma (HB) with lung metastasis in children.Patients and Methods: 98 HB patients with lung metastases admitted to Beijing Tongren Hospital, Capital Medical University were collected and analysed.Results 64 patients had lung metastases at diagnosis (median age, 22.3 months). 34 patients developed lung metastases whilst on treatment (median time, 6.5 months). The time of diagnosis of lung metastasis in patients with HB did not significantly affect survival time or 3-year survival rate (P = 0.37). The survival time and 5-year survival rate of patients with standard treatment was significantly longer than that of without standard treatment (P < 0.001). The survival time and 3-year survival rate of patients with lung metastasis alone or underwent lung metastasectomy was significantly longer than that of patients with extrapulmonary involvement or without lung metastasectomy (P = 0.007, P = 0.099). Lung metastasis accompanied with extrapulmonary involvement was risk factors affecting prognosis (HR = 0.460, 95% CI 0.239–0.888).Conclusions The overall prognosis of HB with lung metastasis in children was poor, and the prognosis of patients with lung metastasis alone was better than those with extrapulmonary involvement. Standardized treatment and resection of lung tumor may prolong the survival of HB patients with lung metastasis.

scholarly journals Lung Metastasis of Primary Alveolar Soft-Part Sarcoma Occurring 20 Years after Initial Treatment

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
R. F. Falkenstern-Ge ◽  
M. Kimmich ◽  
M. Wohlleber ◽  
A. Grabner ◽  
G. Friedel ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Lung Metastasis ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Soft Part ◽  
Lower Limbs ◽  
Alveolar Soft Part Sarcoma ◽  
Malignant Soft Tissue Tumor ◽  
Previously Treated ◽  
The Right

A 30-year old woman was referred to our center because of suspicion of a primary lung tumor of the right upper lobe. Histological examination of the lung lesion revealed lung metastasis of a previously treated alveolar soft part sarcoma of the musculus vastus medialis of the right femur, which was resected 20 years ago. Alveolar soft-part sarcoma is a rare malignant tumor that occurs most often in the soft tissue of lower limbs. It is a slow-growing malignant soft tissue tumor arising in muscle tissue, usually in young adults. Due to pleural and extensive mediastinal infiltration with bilateral lung metastases, a systemic treatment with chemotherapy doxorubicin and ifosfamide was initiated. Late metastases from previously treated alveolar part sarcoma should be considered in patients with suspicious lung lesions even if surgical treatment was performed a long time ago.

Hepatocellular carcinoma presenting with lung metastasis: Clinical characteristics and prognostic factors

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15604-e15604
Author(s):  
Y. Kojima ◽  
H. Ueno ◽  
T. Okusaka ◽  
C. Morizane ◽  
S. Kondo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factors ◽  
Survival Time ◽  
Lung Metastasis ◽  
Proportional Hazards Model ◽  
Lung Metastases ◽  
Univariate Analysis ◽  
Previous History ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model

e15604 Background: The efficacy of systemic chemotherapy for hepatocellular carcinoma (HCC) has been limited, but sorafenib has changed the strategy treating for metastatic HCC. The lung is one of the most common metastatic sites for HCC. Therefore, we focused on clinical features and prognostic factors of HCC patients (pts) with lung metastasis in this study. Methods: Between January 2000 and April 2008, 1,117 HCC pts were admitted into our division. During this period, extrahepatic metastasis was detected in 286 pts, and the initial metastatic site was lung in 130 pts. The relationships between the characteristics of these pts at the time of lung metastasis detection and prognosis were examined. Results: There were 107 males and 23 females. Median age was 64 years. The Child-Pugh classification was A in 84 pts, B in 32 pts. HCV Ab was positive in 57 pts, HBs Ag was positive in 46 pts, and both were negative in 27 pts. The median survival time of all pts was 298 days. Univariate analysis revealed 12 of the 20 variables evaluated to be significantly associated with survival time: number of lung metastasis, presence of intrahepatic HCC, maximum size of intrahepatic HCC, presence of tumor thrombus, AFP, PIVKA II, albumin, prothrombin time, ALP, presence of ascites, Child-Pugh classification, and previous history of hepatic resection. Multivariate analysis using the Cox proportional hazards model demonstrated a lower number (≤5) of lung metastases (p<0.0001), the absence of intrahepatic HCC (p=0.0002), and the absence of ascites (p=0.0339) to be independent favorable prognostic factors. Conclusions: These results may provide useful reference data for determining treatment strategies and planning further clinical trials involving HCC patients with lung metastasis. No significant financial relationships to disclose.

scholarly journals Papillary thyroid microcarcinoma with lung metastases: a case report and review of the literature

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Tadafumi Shimizu ◽  
Takaaki Oba ◽  
Tatsunori Chino ◽  
Ai Soma ◽  
Mayu Ono ◽  
...  
Keyword(s):  
Lung Metastasis ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Standard Of Care ◽  
Distant Metastases ◽  
Needle Aspiration ◽  
Papillary Thyroid Microcarcinoma ◽  
Papillary Thyroid ◽  
Thyroid Microcarcinoma ◽  
The Right

Abstract Background Distant metastasis from papillary thyroid microcarcinoma (PTMC) is rare. Here we report a case of PTMC with multiple lung metastases. Case presentation A 64-year-old man presented to our hospital with abdominal pain. Computed tomography incidentally revealed multiple lung nodules. The lung tumor was histologically diagnosed as metastasis of papillary thyroid carcinoma (PTC) by core needle biopsy via thoracoscopy. The patient was referred to our department for further examination. Neck ultrasonography revealed a 0.9 cm hypoechoic nodule in the right lobe of the thyroid gland, which was diagnosed as PTC by fine-needle aspiration cytology. Subsequently, total thyroidectomy was performed, followed by radioiodine therapy. Iodine-131 (131-I) scintigraphy showed a strong accumulation in the lung metastasis. The patient presented no evidence of progression of lung metastasis for 25 months after the operation. Conclusions Lymph node metastasis or extraglandular extension has been reported in the few published cases of metastatic PTMC, including the present case, and the average age of these cases was 58.8 ± 12.0 years. Although active surveillance without surgical resection is expected to become a standard of care for PTMC, this case indicates that a subset of PTMC patients with risk factors may develop distant metastases. Hence, careful preoperative screening is required to avoid complications associated with completion thyroidectomy.

scholarly journals Papillary Thyroid Microcarcinoma with Lung Metastases: A Case Report and Review of the Literature

2021 ◽  
Author(s):  
Tadafumi Shimizu ◽  
Takaaki Oba ◽  
Tatsunori Chino ◽  
Ai Soma ◽  
Mayu Ono ◽  
...  
Keyword(s):  
Thyroid Gland ◽  
Lung Metastasis ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Distant Metastases ◽  
Needle Aspiration ◽  
Papillary Thyroid Microcarcinoma ◽  
Papillary Thyroid ◽  
Thyroid Microcarcinoma ◽  
Remnant Thyroid

Abstract Introduction: Distant metastasis from papillary thyroid microcarcinoma (PTMC) is rare. Here we report a case of PTMC with multiple lung metastases.Case Presentation: A 64-year-old man presented to our hospital with abdominal pain. Computed tomography incidentally revealed multiple lung nodules. The lung tumor was histologically diagnosed as metastasis of papillary thyroid carcinoma (PTC) by core needle biopsy via thoracoscopy. The patient was referred to our department for further examination. Neck ultrasonography revealed a 0.8 cm hypoechoic mass in the right lobe of the thyroid gland, diagnosed as PTC by fine-needle aspiration cytology. Subsequently, total thyroidectomy was performed, followed by radioiodine therapy. Iodine-131 (131-I) scintigraphy showed a strong accumulation in the lung metastasis. The patient presented no evidence of progression of lung metastasis for 25 months after the operation. Discussion/Conclusions: Although there are few published cases of metastatic PTMC, lymph node metastasis or extraglandular extension was observed in most patients, including the present case, and the average age of these cases was 58.8 ± 12.0 years. Although active surveillance without surgical resection is expected to remain standard of care for PTMC, this case indicates that a subset of PTMC patients with risk factors may develop distant metastases. Careful preoperative screening is required to avoid complications associated with reoperation of the remnant thyroid gland.

scholarly journals Development and validation of a nomogram to predict synchronous lung metastases in patients with ovarian cancer: a large cohort study

2020 ◽  
Vol 40 (11) ◽  
Author(s):  
Yufei Yuan ◽  
Fanfan Guo ◽  
Ruoran Wang ◽  
Yidan Zhang ◽  
Guiqin Bai
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Lung Metastasis ◽  
Cox Regression ◽  
Lung Metastases ◽  
Newly Diagnosed ◽  
Discriminative Ability ◽  
Factors Affecting ◽  
Cox Regression Analysis

Abstract Purpose: Lung metastasis is an independent risk factor affecting the prognosis of ovarian cancer patients. We developed and validated a nomogram to predict the risk of synchronous lung metastases in newly diagnosed ovarian cancer patients. Methods: Data of ovarian cancer patients from the Surveillance, Epidemiology, and Final Results (SEER) database between 2010 and 2015 were retrospectively collected. The model nomogram was built on the basis of logistic regression. The consistency index (C-index) was used to evaluate the discernment of the synchronous lung metastasis nomogram. Calibration plots were drawn to analyze the consistency between the observed probability and predicted probability of synchronous lung metastases. The Kaplan–Meier method was used to estimate overall survival rate, and influencing factors were included in multivariate Cox regression analysis (P&lt;0.05) to determine the independent prognostic factors of synchronous lung metastases. Results: Overall, 16059 eligible patients were randomly divided into training (n=11242) and validation cohorts (n=4817). AJCC T, N stage, bone metastases, brain metastases, and liver metastases were evaluated as predictors of synchronous lung metastases. Finally, a nomogram was constructed. The nomogram based on independent predictors was calibrated and showed good discriminative ability. Mixed histological types, chemotherapy, and primary site surgery were factors affecting the overall survival of patients with synchronous lung metastases. Conclusion: The clinical prediction model has high accuracy and can be used to predict lung metastasis risk in newly diagnosed ovarian cancer patients, which can guide the treatment of patients with synchronous lung metastases.

scholarly journals Development and Validation of Nomograms to Predict Lung Metastases in Patients with Ovarian Cancer: A Large Cohort Study

2020 ◽  
Author(s):  
Yufei Yuan ◽  
Fanfan Guo ◽  
Ruoran Wang ◽  
Yidan Zhang ◽  
GuiQin Bai
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Cancer Patients ◽  
Lung Metastasis ◽  
Cox Regression ◽  
Validation Cohort ◽  
Lung Metastases ◽  
Overall Survival Rate ◽  
Newly Diagnosed

Abstract Background Lung metastasis, an independent risk factor affecting the prognosis of patients with ovarian cancer, is associated with poor survival. We tried to develop and validate a nomogram to predict the risk of lung metastases in newly diagnosed patients with ovarian cancer.Methods Patients diagnosed with ovarian cancer from the surveillance, epidemiology and final results (SEER) database between 2010 and 2015 were retrospectively collected. The model nomogram was built based on logistic regression. The consistency index (C-index) was used to evaluate the discernment of the lung metastasis nomogram. Calibration plots was drawn to analyze the consistency between the observed probability and predicted probability of lung metastases in patients with ovarian cancer. The Kaplan-Meier method was used to estimate the overall survival rate, and the influencing factors were included in the multivariate Cox regression (P<0.05) to analyze the independent prognostic factors of lung metastases.Results A total of 16,059 eligible patients were randomly divided into training (n = 11242) and validation cohort (n = 4817). AJCC T, N stage, bone metastases, brain metastases and liver metastases were evaluated as predictors of lung metastases. Finally, a nomogram was constructed. The nomogram based on independent predictors was well calibrated and showed good discriminative ability. The C index is 0.761 (0.736-0.787) for the training cohort and 0.757（0.718-0.795）for the validation cohort. The overall survival rate of ovarian cancer patients with lung metastases was reduced. Mixed histological types, chemotherapy and primary site surgery were factors that affect the overall survival of ovarian cancer patients with lung metastases.Conclusion: The clinical prediction model had high accuracy and can be used to predict the lung metastasis risk of newly diagnosed patients with ovarian cancer, which can guide the treatment of patients with lung metastases.

scholarly journals Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chaiwat Tawarungruang ◽  
Narong Khuntikeo ◽  
Nittaya Chamadol ◽  
Vallop Laopaiboon ◽  
Jaruwan Thuanman ◽  
...  
Keyword(s):  
Survival Rate ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Cox Regression ◽  
Survival Rates ◽  
Care Program ◽  
Tumor Location ◽  
Northeast Thailand ◽  
Curative Surgery

Abstract Background Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival. Methods This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs. Results Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0–3.6), with median survival time of 17.8 months (95% CI: 15.4–20.2), and 5-year survival rate of 24.6% (95% CI: 20.7–28.6). The longest median survival time was 21.8 months (95% CI: 16.3–27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8–46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9–63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4–58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01–2.09; P = 0.013) compared to ICCA+ID patients. Conclusions Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.

scholarly journals Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Tong Shen ◽  
Jing-Lin Liu ◽  
Chu-Yi Wang ◽  
Youlutuziayi Rixiati ◽  
Shi Li ◽  
...  
Keyword(s):  
B Cells ◽  
Lung Metastasis ◽  
Lung Metastases ◽  
Pdz Domain ◽  
Clinical Samples ◽  
Key Factors ◽  
Combined Use ◽  
Iga Production

AbstractThe mechanisms and key factors involved in tumor environments for lung metastasis of CRC are still unclear. Here, using clinical samples from lung metastases of CRC patients, we found that intestinal immune network for IgA production was significantly dysregulated in lung metastases of CRC. Single-cell RNA sequencing discovered a subtype of B cells positive for Erbin, one member of the leucine-rich repeat and PDZ domain (LAP) family, was involved in the lung metastases. Erbin deletion in B cells suppressed lung metastasis of CRC in vivo. And, deletion of Erbin in B cells enhanced the killing effects of CD8+ T cells on tumor cells. Mechanistically, Erbin knockout attenuated TGFβ-mediated suppression of migration of CXCR5+ IgA+ cells and STAT6-mediated PD1 expression. Our study uncovered a key role of Erbin in regulating PD1+ IgA+ B cells in lung metastasis of CRC. Targeting Erbin as well as combined use of neutralizing B cells and antibodies neutralizing PD1 suppresses lung metastasis of CRC in mice, suggesting the potential option for treatment of lung metastasis of CRC.

scholarly journals Octreotide in the therapy of recurrent medulloblastomas

2006 ◽  
Vol 14 (1-2) ◽  
pp. 26-29 ◽  
Author(s):  
Ivan Stefanovic ◽  
Nebojsa Stojanovic ◽  
Dragan Stojanov ◽  
Dragan Dimov
Keyword(s):  
Survival Rate ◽  
Magnetic Resonance ◽  
Survival Time ◽  
Craniospinal Irradiation ◽  
Metastatic Recurrence ◽  
Antitumoral Effect ◽  
Methods Of Treatment ◽  
Cerebellar Metastases

BACKGROUND: Recurrence of medulloblastoma appears after 30% to 40% of the surgeries. Different from primary medulloblastoma, in which five-year survival rate is 50%, the survival time of relapses much shorter and only 20% of the patients manage to survive a year. There is a logical need for additional methods of treatment of recurrent medulloblastomas. The aim of the study is to determine the effects of intracavitary and long-term subcutaneous application of Sandostatin (octreotide) on the recurrent medulloblastomas. METHODS: Fourteen children aged 4 to 9 years, in which, despite of craniospinal irradiation and chemotherapy came to a recurrence of medulloblastoma during the first 6 months after the surgery, were treated subcutaneously with Sandostatin (octreotide) in a longer period of time. Cerebellar medulloblastomas with a diameter bigger than 20 mm and spinal over 10 mm were removed operatively and octreotide with Beriplast was applied intracavitary. RESULTS: Magnetic resonance of cranioaxis shows that the application of octreotide has caused the disappearance of spinal drop metastases in all 7 patients and the cerebellar metastases smaller than 5 mm in all 4 patients. Subcutaneous application of octreotide combined with intracavitary expresses an antitumoral effect in 2/3 of the relapses. The application of octreotide results with a transformation of Chang's stage M0 into M1 in 71.43% of the patients. CONCLUSION: In the case of in loco or metastatic recurrence of medulloblastomas, intracavitarily and subcutaneously applied octreotide results with a regression of the tumor in a 3 year time within 2/3 of the treated patients.

Sign in / Sign up

Export Citation Format

Share Document